Sunday, January 18, 2026

Modeling of #H5N1 #influenza virus #kinetics during dairy #cattle #infection suggests the timing of infectiousness

 


Abstract

Since early-2024 unprecedented outbreaks of highly pathogenic avian influenza H5N1 clade 2.3.4.4b have been ongoing in dairy cattle in the United States with significant consequences for the dairy industry and public health. Estimation of key epidemiological parameters is required to support outbreak response, including predicting the likely effectiveness of interventions and testing strategies. Here, we pool limited publicly available data from four studies of naturally and experimentally infected dairy cattle. We quantify Ct value trajectories of infected dairy cattle and the relationship between Ct value and the log-titer of infectious virus, a proxy for infectiousness. We estimate that following infection minimum Ct values are rapidly reached within 1–2 days with a population mean Ct value of 15.7 (12.9, 18.4). We identify a threshold Ct value of 21.8 (19.9, 24.6), with values of Ct value above this threshold representing little-to-no infectious viral load. Finally, assuming a direct relationship between Ct value and infectiousness, we estimate the distribution of the duration of infectiousness for dairy cattle (i.e., the duration their Ct value remains below the critical threshold) with a population median of 7.8 (4.1, 13.9) days. Our estimates will be critical inputs to the development of outbreak management guidelines and modeling analyses informing response strategies.

Source: 


Link: https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3003586

____

#Bovine-derived #influenza A virus #H5N1 shows efficient #replication in well-differentiated #human #nasal epithelial cells without requiring genetic #adaptation

 


Abstract

Highly pathogenic avian influenza H5N1 viruses of clade 2.3.4.4b have caused widespread avian mortality and sporadic mammalian infections, raising concerns about their potential for efficient replication in the human population. Efficient replication in the human upper respiratory tract is considered a key barrier to transmission. Here, we demonstrate that an H5N1 virus isolated from bovine milk in Texas in 2024 (H5N1Tex/24) replicates as efficiently as the 2009 pandemic H1N1 virus (H1N1HH4/09) in well-differentiated human nasal epithelial cells. These cells express both avian- and human-type influenza receptors, indicating receptor adaptation is unnecessary for entry. H5N1Tex/24 replicates effectively at 33 degrees Celsius, reflecting nasal cavity temperature, whereas earlier avian H5N1 strains require 37 degrees Celsius, suggesting that H5N1Tex/24 has acquired another key adaptive feature to the human upper respiratory tract. H5N1Tex/24 remains sensitive to interferon-λ (IFN-λ) despite inducing low cytokine levels. Notably, no known mammalian-adaptive mutations such as PB2-E627K were detected. These findings suggest that H5N1Tex/24 possesses intrinsic traits enabling efficient replication in the human upper airways, a critical step toward potential airborne transmission, underscoring the need for vigilant surveillance.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

Federal Food Safety and Veterinary Office, https://ror.org/01hwpsz06, 1.24.m

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.01.16.699876v1

____

#Coronavirus Disease Research #References (by AMEDEO, Jan. 18 '26)

 


    BMJ

  1. MARTIN DS, Doidge JC, Gould D, Shahid T, et al
    The impact of skin tone on performance of pulse oximeters used by NHS England COVID Oximetry @home scheme: measurement and diagnostic accuracy study.
    BMJ. 2026;392:e085535.
    PubMed         Abstract available


    Int J Infect Dis

  2. AMODIO E, Aiello R, Battisti M, Casuccio A, et al
    Past Behavior Predicts Future Protection: Uncovering Key Drivers of Influenza Vaccine Acceptance in Italy in the Post-Pandemic Era.
    Int J Infect Dis. 2026 Jan 8:108379. doi: 10.1016/j.ijid.2026.108379.
    PubMed         Abstract available

  3. SEO G, Joo H, Song K, Kim M, et al
    Static and Dynamic Scoring Systems for Post-acute Sequelae of SARS-CoV-2 in a Korean Cohort.
    Int J Infect Dis. 2026 Jan 9:108378. doi: 10.1016/j.ijid.2026.108378.
    PubMed         Abstract available

  4. PIOVESAN C, Fabiani M, Pezzotti P, Ramigni M, et al
    Mortality for causes unrelated to COVID-19 by number of doses and by time since administration of COVID-19 vaccines: a retrospective cohort analysis in the Treviso province, Italy (2021-2025).
    Int J Infect Dis. 2026 Jan 11:108392. doi: 10.1016/j.ijid.2026.108392.
    PubMed         Abstract available

  5. ZHANG C, Zeng J, Yin L, Han W, et al
    Spatio-temporal dispersal patterns of SARS-CoV-2 in the Chinese mainland following the COVID-19 response adjustment.
    Int J Infect Dis. 2026 Jan 12:108391. doi: 10.1016/j.ijid.2026.108391.
    PubMed         Abstract available


    J Infect

  6. GEERS D, Aguilar-Bretones M, Zaeck LM, Gill PA, et al
    Preferential boosting of SARS-CoV-2 Omicron lineage-specific immune responses by monovalent XBB.1.5 vaccination.
    J Infect. 2026;92:106681.
    PubMed         Abstract available

  7. JABOYEDOFF M, Crisinel PA, Valtuille Z, Fafi I, et al
    Infection-related mortality in children in two European countries, 2015 - 2023: an interrupted time-series analysis.
    J Infect. 2026 Jan 9:106688. doi: 10.1016/j.jinf.2026.106688.
    PubMed         Abstract available

  8. BAIN V, Silva-Avelar I, Correa-Silva S, Matsuo OM, et al
    Immune profile of T-lymphocytes in pediatric patients recovered of COVID-19: A longitudinal report.
    J Infect. 2026 Jan 14:106691. doi: 10.1016/j.jinf.2026.106691.
    PubMed        


    J Med Virol

  9. MERROUCHE NEH, Aboudharam G, Thiol S, Terrer E, et al
    IgE Anti-Beta Coronaviruses Serology in Napoleon Soldiers, France.
    J Med Virol. 2026;98:e70800.
    PubMed         Abstract available

  10. YE J, Xu T, Xu C, Liu X, et al
    Fluorescence Resonance Energy Transfer Assay at the Crossroad: Urgent Reexamination of Assay Design for Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease Inhibitors.
    J Med Virol. 2026;98:e70801.
    PubMed         Abstract available

  11. SANCHEZ-GARCIA M, Tresguerres JAF, Alvarez-Gonzalez M, Hera B, et al
    Oral Melatonin in Critically Ill Patients With COVID-19: A Quasi-Experimental Pragmatic Trial.
    J Med Virol. 2026;98:e70807.
    PubMed         Abstract available

  12. PISIL Y, Shida H, Ruiz SM, Cho K, et al
    Structural Adaptability of IgA and IgM Supports Broad SARS-CoV-2 Variant Neutralization.
    J Med Virol. 2026;98:e70790.
    PubMed         Abstract available

  13. FRATTY IS, Kriger O, Weiss L, Vasserman R, et al
    Epidemiology of Enteroviruses Among Hospitalized Patients in Israel (2016-2024): CNS Involvement, Subtype Variability, and Seasonality.
    J Med Virol. 2026;98:e70810.
    PubMed         Abstract available


    J Virol

  14. ALVARADO RE, Lokugamage KG, Garvanska D, Estes LK, et al
    Key residues in SARS-CoV-2 NSP3 hypervariable region are necessary to modulate early stress granule activity.
    J Virol. 2026 Jan 14:e0200625. doi: 10.1128/jvi.02006.
    PubMed         Abstract available


    JAMA

  15. DILEK S, Rosen J, Levashkevich A, Sharfstein JM, et al
    The US Food and Drug Administration's Regulation of Mifepristone.
    JAMA. 2026 Jan 12. doi: 10.1001/jama.2025.23091.
    PubMed         Abstract available

  16. FATTAH M, Stoffel LA, Bubar KM, Bents SJ, et al
    Trends in County-Level Childhood Vaccination Exemptions in the US.
    JAMA. 2026 Jan 14:e2524407. doi: 10.1001/jama.2025.24407.
    PubMed        


    Lancet

  17. WHITAKER M, Elliott J, Gerard-Ursin I, Cooke GS, et al
    Profiling vaccine attitudes and subsequent uptake in 1.1 million people in England: a nationwide cohort study.
    Lancet. 2026 Jan 12:S0140-6736(25)01912-9. doi: 10.1016/S0140-6736(25)01912.
    PubMed         Abstract available


    Lancet Infect Dis

  18. KAKU Y, Fujiwara M, Uriu K, Yo MS, et al
    Humoral immunity after LP.8.1 monovalent vaccines against a broad range of SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2.
    Lancet Infect Dis. 2026 Jan 12:S1473-3099(25)00772.
    PubMed        

  19. LEITNER DR, Walsh SR, Suzuki M, Desjardins M, et al
    Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial.
    Lancet Infect Dis. 2026 Jan 7:S1473-3099(25)00682.
    PubMed         Abstract available


    N Engl J Med

  20. CAI M, Xie Y, Al-Aly Z
    2024-2025 Covid-19 Vaccine Outcomes in U.S. Veterans. Reply.
    N Engl J Med. 2026;394:307.
    PubMed        

  21. YANG C, Tebbutt SJ
    2024-2025 Covid-19 Vaccine Outcomes in U.S. Veterans.
    N Engl J Med. 2026;394:306-307.
    PubMed        

  22. LAMPERT R, Harmon KG
    Sudden Cardiac Arrest in Athletes.
    N Engl J Med. 2026;394:268-280.
    PubMed         Abstract available


    Nature

  23. ROZMAN B, Broennimann K, Rajan KS, Nachshon A, et al
    N(1)-Methylpseudouridine directly modulates translation dynamics.
    Nature. 2026 Jan 14. doi: 10.1038/s41586-025-09945.
    PubMed         Abstract available


    Science

  24. COHEN J
    Scientists reject call to retest childhood vaccines.
    Science. 2026;391:220-221.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, Jan. 18 '26)

 


    Antiviral Res

  1. LEEKHA A, Reichel K, Hurst B, Varadarajan N, et al
    Therapeutic intranasal delivery of NanoSTING provides broad protection against seasonal and highly pathogenic influenza strains.
    Antiviral Res. 2026 Jan 14:106342. doi: 10.1016/j.antiviral.2026.106342.
    PubMed         Abstract available


    BMJ

  2. MARTIN DS, Doidge JC, Gould D, Shahid T, et al
    The impact of skin tone on performance of pulse oximeters used by NHS England COVID Oximetry @home scheme: measurement and diagnostic accuracy study.
    BMJ. 2026;392:e085535.
    PubMed         Abstract available


    Drug Saf

  3. PALMER M, Seekins D, Avigan M, Marcinak J, et al
    The Impact of COVID-19 and COVID-19 Vaccination on Detection, Assessment, and Management of Suspected Acute Drug-Induced Liver Injury Occurring during Clinical Trials: Consensus Recommendations from the IQ DILI Initiative.
    Drug Saf. 2026;49:9-25.
    PubMed         Abstract available


    Epidemiol Infect

  4. WOLMUTH-GORDON HS, Elgohari S, Dabrera G, Green RE, et al
    Estimating influenza A subtype ratios among critical care admissions in England.
    Epidemiol Infect. 2026 Jan 12:1-8. doi: 10.1017/S0950268825100812.
    PubMed        

  5. KOKAVECZ L, Sohajda Z, David P, Stagel A, et al
    Incidence of parvovirus B19 among Hungarian blood donor population during COVID-19 restrictions and the subsequent B19 epidemic of 2024.
    Epidemiol Infect. 2026;154:e11.
    PubMed         Abstract available

  6. BEJKO D, Vergison A, Stranges S, Mossong J, et al
    Protection from second booster vaccines and natural immunity against SARS-CoV-2 infections, 2022-2023.
    Epidemiol Infect. 2025;154:e10.
    PubMed         Abstract available

  7. CAREY C, O'Moore E, Huyton R, Willner S, et al
    COVID-19 outbreaks in care homes: How does size influence transmission dynamics? A cross-sectional study with implications for outbreak management in small care homes.
    Epidemiol Infect. 2025;154:e8.
    PubMed         Abstract available


    J Clin Microbiol

  8. BIGAUD B, Marjanovic N, Deroche L, Drugeon B, et al
    Impact of multiplex PCR point-of-care platform implementation for respiratory pathogen detection in an emergency department with high daily patient volume.
    J Clin Microbiol. 2026;64:e0131325.
    PubMed         Abstract available


    J Gen Virol

  9. GERODEZ A, Dufrasne FE, Denis O, Steensels M, et al
    The cellular activating protein-1 cFos regulates influenza A virus replication.
    J Gen Virol. 2026;107:002194.
    PubMed         Abstract available


    J Infect Dis

  10. SKOWRONSKI DM, Ranadheera C, Kaweski SE, Sabaiduc S, et al
    Cross-reactive H5N1 neuraminidase antibodies by age and influenza A imprinting cohorts of the past century: population-based serosurvey, British Columbia, Canada.
    J Infect Dis. 2026 Jan 16:jiag030. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  11. CONG G, Li H, Li L, Chen J, et al
    The newly developed porcine-origin parainfluenza virus PIV5-JS17 serves as an exogenous gene delivery system for swine.
    J Virol. 2026 Jan 13:e0185825. doi: 10.1128/jvi.01858.
    PubMed         Abstract available


    J Virol Methods

  12. ZHANG W, Chen XY, Lin SX
    Search and prove of efficient inhibitors against papain-like protease from SARS-CoV-2.
    J Virol Methods. 2026;341:115329.
    PubMed         Abstract available

  13. EPTAMINITAKI GC, Zafiropoulos A, Sourvinos G
    Evaluation of summation operator-MM molecular medium for the SARS-CoV-2 RNA stability over 90 days under different temperature conditions.
    J Virol Methods. 2026;341:115322.
    PubMed         Abstract available


    JAMA

  14. MCCLYMONT E, Blitz S, Forward L, Cole S, et al
    The Role of Vaccination in Maternal and Perinatal Outcomes Associated With COVID-19 in Pregnancy.
    JAMA. 2025 Dec 15:e2521001. doi: 10.1001/jama.2025.21001.
    PubMed         Abstract available


    N Engl J Med

  15. LAMPERT R, Harmon KG
    Sudden Cardiac Arrest in Athletes.
    N Engl J Med. 2026;394:268-280.
    PubMed         Abstract available


    Pediatrics

  16. HAMDAN O, Amarin JZ, Antoon JW, Stopczynski T, et al
    Influenza Antiviral Use in Hospitalized Children Before and During the COVID-19 Pandemic.
    Pediatrics. 2026 Jan 14:e2025071898. doi: 10.1542/peds.2025-071898.
    PubMed         Abstract available


    PLoS Comput Biol

  17. WANG Z, Zhou Z, Wang J, Yang L, et al
    Characterization of the heterogeneity in SARS-CoV-2 fitness dynamics via graph representation learning.
    PLoS Comput Biol. 2026;22:e1013582.
    PubMed         Abstract available

  18. MAYER-BLACKWELL K, Minervina A, Pogorelyy M, Rawat P, et al
    TCR2HLA: Calibrated inference of HLA genotypes from TCR repertoires enables identification of immunologically relevant metaclonotypes.
    PLoS Comput Biol. 2026;22:e1013767.
    PubMed         Abstract available


    PLoS One

  19. ORSOLIC BESLIC A, Caljkusic K, Matana A, Tomelic Ercegovic K, et al
    Evaluation of cerebrovascular reactivity using transcranial Doppler in patients with influenza.
    PLoS One. 2026;21:e0340768.
    PubMed         Abstract available

  20. SCHNEIDER JL, Rivelli JS, Escaron AL, Crocker R, et al
    Impact of COVID-19 on colorectal cancer screening in a federally qualified health center: Provider and staff perspectives.
    PLoS One. 2026;21:e0340184.
    PubMed         Abstract available

  21. VINER RM, Pearce A, Hope S
    The impact of school absence on mental health in children and young people: Analysis of an English national birth cohort.
    PLoS One. 2026;21:e0336137.
    PubMed         Abstract available

  22. MANN H, Dimon E, Zhang Y, Arroyo N, et al
    Impact of COVID-19 restrictions on thyroid cancer diagnoses in a comprehensive cancer center (2017-2023).
    PLoS One. 2026;21:e0340347.
    PubMed         Abstract available

  23. ZENG Z, Sathasivam S, Xin J, Zhao H, et al
    Public participation in healthcare safety: A tripartite evolutionary game model with evidence from diverse international cases.
    PLoS One. 2026;21:e0339304.
    PubMed         Abstract available

  24. RIBEIRO HS, Mondini DR, Santa-Catharina GP, Marcal L, et al
    Skeletal muscle-kidney crosstalk in a cohort of critical illness survivors.
    PLoS One. 2026;21:e0339795.
    PubMed         Abstract available

  25. BAI Y, Cao P, Kim C, Ienciu K, et al
    Longitudinal trends in vaping, smoking, and harmful alcohol use across sexual orientations in the UK (2014-2021).
    PLoS One. 2026;21:e0339847.
    PubMed         Abstract available

  26. AKTER N, Zerin FF, Banu B, Kanta FA, et al
    Quality of life in hypertensive patients using the WHOQOL-BREF instrument in the post-pandemic Bangladesh: A cross-sectional study.
    PLoS One. 2026;21:e0340897.
    PubMed         Abstract available


    Vaccine

  27. DE WALS P, Papenburg J, Gilca R, Brousseau N, et al
    Are hemagglutinin-only influenza vaccines as effective as conventional influenza vaccines against severe infection?
    Vaccine. 2026;74:128234.
    PubMed        

  28. CHENG K, Pullenayegum E, Singh P, Loeb M, et al
    Use of composite outcomes in cluster randomized control trials of influenza vaccines.
    Vaccine. 2026;74:128224.
    PubMed         Abstract available

  29. PAGE CL, Holbrook BC, Miller LD, Grayson JM, et al
    TLR5 versus TLR7/8 agonist-dependent modulation of the early gene expression response to inactivated influenza virus vaccine in newborn nonhuman primates.
    Vaccine. 2026;74:128163.
    PubMed         Abstract available

  30. HARKER EJ, Lewis NM, Johnson CA, Zhu Y, et al
    Differences in influenza vaccine effectiveness by sex among adults hospitalized with acute respiratory illness-IVY network, January 24, 2022-September 1, 2024.
    Vaccine. 2026;74:128192.
    PubMed         Abstract available

  31. DE BRABANDERE L, Herzog SA, Desombere I, Arien KK, et al
    Enhanced immune responses to mRNA compared with adenoviral vector COVID-19 vaccines during pregnancy: implications for pandemic preparedness.
    Vaccine. 2026;73:128153.
    PubMed         Abstract available

  32. ORELLANA-MANZANO A, Garcia-Angulo A, Quinto F, Munizaga MG, et al
    COVID-19 vaccination campaign, knowledge, and trust in Duran, Ecuador: a cross-sectional study.
    Vaccine. 2026;72:127867.
    PubMed         Abstract available

  33. YE G, Qu C, Liao Z, Wu R, et al
    Engineered flagellin-based adjuvant boosts mucosal immunity in recombinant RSV vaccine.
    Vaccine. 2026;73:128190.
    PubMed         Abstract available

  34. ZHU Z, Chen Z, Gao Y, Xie Z, et al
    Genetic distance predicts neutralizing antibody titers for monovalent and bivalent SARS-CoV-2 vaccines.
    Vaccine. 2026;73:128185.
    PubMed         Abstract available

  35. BREZNIK JA, Ang JC, Bhakta H, Liu LM, et al
    Humoral and cellular immunogenicity of sequential heterogeneous bivalent SARS-CoV-2 vaccinations in long-term care and retirement home residents.
    Vaccine. 2025;73:128160.
    PubMed         Abstract available

  36. OKABE H, Hashimoto K, Asano Y, Sato M, et al
    Adverse events post-BNT162b2 vaccination in Japanese children.
    Vaccine. 2025;73:128167.
    PubMed         Abstract available

  37. DANIEL N, Smith C, Miah N, Akroyd C, et al
    Enablers and barriers to participation in vaccine trials: a narrative synthesis.
    Vaccine. 2025;73:128183.
    PubMed         Abstract available

  38. REITER PL, Katz ML
    Vaccine hesitancy among midlife and older adults in the United States.
    Vaccine. 2025;72:128054.
    PubMed         Abstract available

  39. BALLOUT S, Darwish SA, Kelly PJ, Keller T, et al
    The use of storytelling in COVID-19 vaccine promotion: A scoping review of interventions and campaigns.
    Vaccine. 2025;72:128098.
    PubMed         Abstract available

  40. PARIDANS M, Gillain N, Husson E, Darcis G, et al
    COVID-19 vaccination: Does knowledge of higher immunity influence first and second COVID-19 booster uptake? A study carried out in a university population.
    Vaccine. 2025;72:128057.
    PubMed         Abstract available

  41. PAL SS, Kim KH, Bhatnagar N, Grovenstein P, et al
    A combination of new prefusion mRNA and protein vaccines enhances neutralizing antibodies and protection against respiratory syncytial virus.
    Vaccine. 2025;73:128154.
    PubMed         Abstract available

  42. ALVES K, Kouassi A, Nelson J, Plested JS, et al
    Safety and immunogenicity of a single dose of a JN.1 variant COVID-19 vaccine in previously vaccinated adults: Primary analysis report of a phase 3 open-label trial.
    Vaccine. 2025;73:128164.
    PubMed         Abstract available

  43. MIRON E, Sauvageau C, Dube E, Vivion M, et al
    Vaccine hesitancy among older adults, urban indigenous and newcomers in Canada: A qualitative comparative study.
    Vaccine. 2025;73:128143.
    PubMed         Abstract available

  44. STRENG BMM, Hensen LCM, Delemarre EM, Binnendijk RS, et al
    Antibody concentration and function following SARS-CoV-2 vaccination decrease with age in adults and children with Down syndrome.
    Vaccine. 2025;73:128079.
    PubMed         Abstract available

  45. LARSEN FD, Juhl AK, Dietz LL, Nielsen H, et al
    Immunogenicity of SARS-CoV-2 primary vaccination and boosters in patients with immune-mediated inflammatory diseases: Impact of immunosuppressive therapy.
    Vaccine. 2025;73:128155.
    PubMed         Abstract available

  46. SEESKIN ZH, Steffan M, Geistwhite B, Yarbrough M, et al
    Using latent class analysis of survey data to explore parent behaviors and attitudes regarding children's COVID vaccinations.
    Vaccine. 2025;73:128149.
    PubMed         Abstract available

  47. TIPTON T, Laidlaw S, Nguyen D, Longet S, et al
    ACE2 inhibition ELISA is an effective surrogate for SARS-CoV-2 live virus neutralisation.
    Vaccine. 2026;72:128123.
    PubMed         Abstract available

  48. KOVACS D, Brar G, Anthony SJ, Wang LF, et al
    Initiation of a coronavirus vaccine library.
    Vaccine. 2025;72:128140.
    PubMed         Abstract available

  49. HARO SLY MJ, Zubeldia L
    COVID-19 vaccine production and the technological gap in the Global South: The cases of Argentina and Brazil.
    Vaccine. 2025;72:128141.
    PubMed         Abstract available

  50. JABBAR F, Kadhim KA, Alhilfi RA, Al Khafaji IS, et al
    Advancements in monitoring adverse events following immunization in Iraq: Insights from the CIVIE project 2022-2023.
    Vaccine. 2026;72:128121.
    PubMed         Abstract available

  51. SINCLAIR JE, Mayfield HJ, Lu H, Brown SJ, et al
    Estimating risk of long COVID using a Bayesian network-based decision support tool.
    Vaccine. 2026;72:128127.
    PubMed         Abstract available

  52. DRISLANE S, Moore H, Attwell K
    Understanding parental decisions to decline or delay infant RSV immunisation, nirsevimab, in Western Australia in 2024.
    Vaccine. 2026;72:128133.
    PubMed         Abstract available

  53. MADIA JE, Nicodemo C, Petrou S, de Lusignan S, et al
    Primary healthcare costs associated with the AstraZeneca COVID-19 vaccine in England.
    Vaccine. 2025;72:128067.
    PubMed         Abstract available

  54. HAYASHI K, Hashimoto N, Hashimoto C, Takeuchi Y, et al
    Effect of completed COVID-19 vaccination on serum interferon lambda3: a single-center retrospective study.
    Vaccine. 2025;72:128108.
    PubMed         Abstract available


    Virology

  55. THOMAS MH, Carlock MA, Ross TM
    Adjuvants enhance protective antibodies against seasonal influenza viruses following a single vaccination of Fluzone.
    Virology. 2026;616:110787.
    PubMed         Abstract available

  56. IINO Y, Sato K, Furuse Y, Isogai E, et al
    Human parainfluenza virus type 3 viruses with the furin-susceptible motif at the cleavage site of the fusion protein arose from original wild strains during their propagation in vitro.
    Virology. 2026;617:110797.
    PubMed         Abstract available


    Virus Res

  57. CAI H, Hou L, Chang J, Yang Q, et al
    Venenum bufonis and its active constituents alleviate RSV-induced pneumonia in mice by suppressing macrophage infiltration and NLRP3 inflammasome activation.
    Virus Res. 2026;363:199672.
    PubMed         Abstract available

Saturday, January 17, 2026

History of Mass Transportation: The FIAT Autorail TER RENFE, Madrid Atocha (1981)

 


Di Smiley.toerist - File:Madrid Atocha 1981.jpg, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=19532692

Source: 


Link: https://it.wikipedia.org/wiki/Fiat_Ferroviaria

____

#Polymerase #mutations underlie early #adaptation of #H5N1 #influenza virus to dairy #cattle and other #mammals

 


Abstract

In 2024, an unprecedented outbreak of H5N1 high pathogenicity avian influenza was detected in dairy cattle in the USA resulting in spillbacks into poultry, wild birds and other mammals including humans. Here, we present molecular and virological evidence that the cattle B3.13 genotype H5N1 viruses rapidly accumulated adaptations in polymerase genes that enabled better replication in bovine cells and tissues, as well as cells of other mammals including humans. We find evidence of several mammalian adaptations in cattle including PB2 M631L, which is found in all cattle sequences, and PA K497R, which is found in the majority. Structurally, PB2 M631L maps to the polymerase-ANP32 interface, an essential host factor for viral genome replication. We show that this mutation adapts the polymerase to better interact with bovine ANP32 proteins, particularly ANP32A, and thereby enhances virus replication in bovine mammary systems and primary human airway cultures. We show that ongoing evolution in the PB2 gene, including E627K and a convergently arising D740N substitution, further increase polymerase activity and virus replication in a range of mammalian cells. Thus, circulation of H5N1 in dairy cattle allows virus adaption improving replicative ability in cattle and poses a continued risk of zoonotic spillover.

Source: 


Link: https://www.nature.com/articles/s41467-026-68306-6

____

History of Mass Transportation: The FS ATR 100 Diesel Autorail in Turin (1959)

 


Di Brooksbank - Opera propria, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=38676394

Source: 


Link: https://it.wikipedia.org/wiki/Fiat_Ferroviaria

____

Friday, January 16, 2026

Thrombotic Events and #Stroke in the Year After #COVID19 or Other Acute Respiratory #Infection

 


Abstract

Previous studies have documented an increased risk for thrombotic events 30 days after COVID-19 infection, but less is known about this risk beyond 30 days or compared with risk after other infectious acute respiratory illnesses (ARIs). By using PCORnet data from April 1, 2022–April 30, 2023, we compared the incidences of thrombotic events in the year after COVID-19 illness with other ARI diagnoses in hospitalized and nonhospitalized patients. Overall, the risk for any thrombotic event was higher among patients with COVID-19 compared with patients with other ARIs (incidence ratio 1.63; p<0.05). Nonhospitalized patients with COVID-19 had a 73% increased risk for a thrombotic event in the year after acute illness compared with nonhospitalized patients with ARI (p<0.05). The increased risk for thrombotic events in the year after COVID-19 emphasizes the need for stroke awareness for patients and healthcare professionals.

Source: 


Link: https://wwwnc.cdc.gov/eid/article/32/13/25-0630_article

____

#Genetic Diversity of the Non-Polio #Enteroviruses Detected in Samples of Patients with Aseptic #Meningitis in the #Ural Federal District and Western #Siberia

 


Abstract

Human non-polio enteroviruses (NPEVs) cause a plethora of infections in humans, ranging from mild to severe neurological diseases including aseptic meningitis. NPEVs are the leading cause of aseptic meningitis in both children and adults worldwide. In Russia, reports of NPEV infections have surged, especially in the post-COVID era starting in 2022, with elevated infection rates into 2023. A comprehensive examination of the whole genome is crucial for understanding the evolution of NPEV genes and for predicting potential outbreaks. This study focused on identifying the circulating NPEV strains in the Ural Federal District and Western Siberia, using Sanger sequencing and next-generation sequencing (NGS) methodologies. Biological samples were collected from (n = 225) patients diagnosed with aseptic meningitis. Bioinformatics analysis targeted the nucleotide sequences of the major capsid protein (partial VP1) gene fragment, and the assembly of whole NPEV genomes. A total of 159 NPEVs were characterized, representing 70.7% of the collected samples. The main capsid variants forming the predominant genotypic profile included E30 (n = 39, 24.3%), E6 (n = 31, 19.3%), and CVA9 (n = 25, 15.6%). Using NGS, we successfully assembled 13 whole genomes for E6, E30, EV-B80, CVA9, CVB5, E11, and EV-A71 and 3 partial genomes for E6 and EV-B87. This molecular-genetic analysis provides contemporary insights into the genotypic composition, circulation patterns, and evolutionary dynamics of the dominant NPEV associated with aseptic meningitis in the Ural Federal District and Western Siberia. The laboratory-based monitoring and epidemiological surveillance for genetic changes and evolutionary studies are important for improving prevention and healthcare.

Source: 


Link: https://www.mdpi.com/1999-4915/18/1/121

____

#USA, #Wastewater Data for Avian #Influenza #H5 (#CDC, Jan. 16 '26)

 


{Excerpt}

Time Period: January 04, 2026 - January 10, 2026

-- H5 Detection8 site(s) (1.5%)

-- No Detection541 site(s) (98.5%)

-- No samples in last week66 site(s)




(...)

Source: 


Link: https://www.cdc.gov/nwss/rv/wwd-h5.html

____

#Ukraine - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 


Two mute swans in Kyiv City.

Source: 


Link: https://wahis.woah.org/#/in-review/7201

____

#Moldova - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification



Two mute swan in Teleneşti Region.

Source: 


Link: https://wahis.woah.org/#/in-review/7195

____

Thursday, January 15, 2026

#Sweden - #Influenza A #H5N2 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 


A Barnacle goose was found diseased and was euthanized. It was sent to the Swedish Veterinary Agency for laboratory analysis as part of the national surveillance program for avian influenza. {Sölvesborg Region}

Source: 


Link: https://wahis.woah.org/#/in-review/7191

____

Genetic Characterization and Evolutionary #Insights of Novel #H1N1 Swine #Influenza Viruses Identified from #Pigs in #Shandong Province, #China

 


Abstract

Influenza A viruses exhibit broad host tropism, infecting multiple species including humans, avian species, and swine. Swine influenza virus (SIV), while primarily circulating in porcine populations, demonstrates zoonotic potential with sporadic human infections. In this investigation, we identified two H1N1 subtype swine influenza A virus strains designated A/swine/China/SD6591/2019(H1N1) (abbreviated SD6591) and A/swine/China/SD6592/2019(H1N1) (abbreviated SD6592) in Shandong Province, China. The GenBank accession numbers of the SD6591 viral gene segments are PV464931-PV464938, and the GenBank accession numbers corresponding to each of the eight SD6592 viral gene segments are PV464939-PV464946. Phylogenetic and recombination analyses suggest potential evolutionary differences between the isolates. SD6591 displayed a unique triple-reassortant genotype: comparative nucleotide homology assessments demonstrated that the PB2, PB1, NP, NA, HA, and NEP genes shared the highest similarity with classical swine-origin H1N1 viruses. In contrast, SD6592 maintained genomic conservation with previously characterized H1N1 swine strains, although neither of these two isolates exhibited significant intrasegmental recombination events. Through comprehensive sequence analysis of these H1N1 SIVs, this study provides preliminary insights into their evolutionary history and underscores the persistent risk of cross-species transmission at the human–swine interface. These findings establish an essential foundation for enhancing national SIV surveillance programs and informing evidence-based prevention strategies against emerging influenza threats.

Source: 


Link: https://www.mdpi.com/1999-4915/18/1/117

____

The Decline in #Influenza #Antibody Titers and Modifiers of #Vaccine #Immunity from over Ten Years of Serological Data

 


Abstract

Annual influenza vaccination is the cornerstone for seasonal protection, yet antibody responses are highly variable across individuals and over time. To systematically assess the determinants of this heterogeneity, we compiled 20,449 hemagglutination inhibition and neutralization titers from 4,540 participants enrolled in 14 new vaccine studies we conducted and 50 prior studies that collectively span 2010-2023. Seasonal effects dominated, with pre- and post-vaccination titers declining steadily from 2017 onwards, outweighing the influence of age, sex, or repeated vaccination. Titers to B Yamagata remained steady throughout all years examined, suggesting unique durability and offering a reason for lineage extinction. Vaccine timing emerged as a strong and previously underappreciated determinant of immunity, with individuals vaccinated later in the season exhibiting larger post-vaccination titers. Not being vaccinated or receiving the live-attenuated FluMist vaccine in one year significantly enhanced the response to inactivated vaccines in 45% or 68% of cohorts, respectively, whereas antigen dose and adjuvants had modest impact. These findings identify vaccine timing and seasonal context as underrecognized drivers of immunogenicity and provide actionable insights for optimizing influenza vaccination strategies.


Competing Interest Statement

The authors have declared no competing interest.


Funding Statement

This research was supported by the the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under the Computational Models of Influenza Immunity (U01 AI187062), LJI & Kyowa Kirin, Inc. (KKNA - Kyowa Kirin North America), and the Bodman family (TE).

Source: 


Link: https://www.medrxiv.org/content/10.64898/2026.01.07.25342310v1

____

Wednesday, January 14, 2026

An #mRNA #influenza #vaccine induces #immunity comparable to an adjuvanted vaccine in a randomized trial

 


Abstract

Influenza causes substantial morbidity and mortality worldwide. This randomized, open-label, phase 1 trial (ClinicalTrials.gov, NCT05397223, date of registration: May 31, 2022) compared the immunogenicity of an mRNA-based quadrivalent influenza hemagglutinin (HA) vaccine (mRNA-1010) with a licensed comparator (FLUAD) in adults aged 18-75 years. We evaluated humoral and cellular immune responses using hemagglutination inhibition assays, flow cytometry-based memory B cell (MBC) profiling, and intracellular cytokine staining for T-cell characterization. Both vaccines elicited durable hemagglutination inhibition titers and increased HA-specific MBC responses across four vaccine strains. Compared with FLUAD, mRNA-1010 induced higher frequencies of classical and activated MBCs specific to the H3 HA included in the vaccine, while inducing similar MBC responses to the other strains. mRNA-1010 and FLUAD generated strong HA-specific CD4+ T-cell responses; a trend toward higher CD8+ T-cell responses was observed in mRNA-1010 recipients compared with FLUAD recipients for two of the four strains. These findings support the potential of the mRNA platform for seasonal influenza vaccination.

Source: 


Link: https://www.nature.com/articles/s41541-026-01370-7

____

#Genomic Insights into #Marburg Virus Strains from 2023 and 2025 #Outbreaks in Kagera, #Tanzania

 


Abstract

Marburg virus (MARV) is the primary cause of Marburg virus disease (MVD), a severe hemorrhagic fever with a high case-fatality rate. The first reported MVD outbreak in Tanzania occurred in 2023, followed by a second outbreak in 2025, both within the Kagera region. During those MVD outbreaks, 174 suspected cases were identified; of those, 10 were laboratory confirmed. After complete genome assembly and bioinformatic analyses, we found the MARV strains of the 2023 and 2025 outbreaks to be closely related and clustered with MARV strains that caused outbreaks in Rwanda (2024) and Uganda (2014). The sequences from both MVD outbreaks in Tanzania showed >99.71% nucleotide identity, suggesting a possible single spillover event followed by limited human-to-human virus transmission. Further ecologic studies are essential to identify potential spillover events, but our findings indicate that closely related MARV strains circulate in Kagera, Tanzania, posing a risk for future outbreak recurrence.

Source: 


Link: https://wwwnc.cdc.gov/eid/article/32/1/25-1314_article

____

#Trends in #heart #failure prevalence in post-disaster #Fukushima residents 2015–2021

 


Abstract

This study aimed to investigate the prevalence of heart failure (HF) among adults aged ≥ 40 years using health checkup and medical claim data in Fukushima from 2015 to 2021. Joinpoint regression and age-period-cohort analyses were conducted to estimate temporal trends. Age-standardized prevalence and hospital admission rates for HF were 37.0 and 7.4/1000 and 25.9 and 5.3/1000 for men and women, respectively. The prevalence was significantly higher in the coastal area and evacuation zone designated after the 2011 disaster compared to the prefecture overall. In men, the prevalence increased continuously, with an average annual percentage change (AAPC) ranging from 0.72% (evacuation zone) to 1.15% (mountainous area) (P < 0.05). In total residents, the AAPC was significant only in the mountainous areas (0.78%, P = 0.021). Age-period-cohort analysis showed a net drift of 2.50% (95% CI 1.88–3.13%) in men and 0.76% (95% CI − 0.17–1.70%) in women. Cohort rate ratios increased significantly in men born between 1925 and 1975, while in women, they decreased for those born between 1925 and 1960 but increased for those born between 1960 and 1970. The prevalence of HF varied across post-disaster areas of Fukushima. Given that pathological changes and modifiable risk factors for HF accumulate gradually, continuous monitoring among middle-aged adults is essential to enable timely prevention and targeted intervention.

Source: 


Link: https://www.nature.com/articles/s41598-026-36032-0

____

#Molecular basis of 60 years of #antigenic #evolution of #human #influenza #H3N2 virus neuraminidase

 


Highlights

• Human influenza A virus N2 neuraminidases were analyzed by antigenic cartography

• N2 antigenic evolution was discordant with antigenic evolution of H3 hemagglutinin

• Important epitopes were identified at the NA active site but also elsewhere in NA

• Changes in charge, volume, and hydropathy of epitope residues caused antigenic drift


Summary

Human influenza A viruses escape antibody-mediated immunity through changes in the hemagglutinin (HA) and neuraminidase (NA) glycoproteins. HA antigenic evolution has been studied extensively, with more recent interest in NA due to its importance in influenza vaccine efficacy. Here, the antigenic properties of the NA of more than 300 A(H3N2) and A(H2N2) viruses isolated since 1957 were quantified with a NA inhibition enzyme-linked lectin assay and visualized using antigenic cartography, with follow-up molecular studies using recombinant viruses. The antigenic evolution of N2 NA was more gradual than that described for H3 HA, and antigenic changes in NA and HA were discordant. Multiple substitutions around the NA active site and tetramer lateral side that alter the charge, volume, or hydropathy of amino acids collectively determined antigenic properties. These data facilitate sequence-based genomic surveillance and inference of antigenic phenotypes from genotypes and offer opportunities to improve influenza vaccine effectiveness through increased focus on NA.

Source: 


Link: https://www.cell.com/cell-host-microbe/abstract/S1931-3128(25)00525-6?rss=yes

____

Tuesday, January 13, 2026

A VLP-based #mRNA #vaccine elicits potent humoral and cellular #immunity against #Oropouche virus

 


ABSTRACT

Oropouche virus (OROV) is reemerging in the Americas, along with a growing threat to global public health. Recent outbreaks have witnessed the first reported fatalities, vertical transmissions, and intercontinental importations of OROV, underscoring its expanding risk. Despite this, no vaccines or specific therapeutics are available, and fundamental research on OROV vaccinology and antigenicity remains limited. Here, we show that co-expression of the M polyprotein and nucleocapsid protein (NP) drives the assembly of OROV virus-like particles (VLPs) with high immunogenicity. Using the prototype strain OROV/sloth/Brazil/PA-UG-BeAn19991/1960, we developed an mRNA vaccine, M/N-vac, encoding these VLPs. Immunization with M/N-vac in mice elicited robust OROV-specific IgG and pseudovirus-neutralizing antibodies that cross-reacted with a contemporary circulating strain, hOROV/Brazil/AM-UKY-AM0088/2024. The vaccine also induced a durable, antigen-specific Th1-biased cellular immune response characterized by high-level interferon-gamma secretion. Additionally, we identified a highly conserved potential immunodominant epitope in BALB/c, N2-3, within the nucleocapsid protein. Furthermore, the VLP-encoding mRNA vaccine induced stronger OROV-specific humoral and cellular immune responses than the VLP protein vaccine. In vivo results based on immunization with M/N-vac demonstrate VLP-based vaccines to be a promising broad-spectrum strategy against OROV while providing novel insights into their antigenicity and design.

Source: 


Link: https://journals.asm.org/doi/full/10.1128/mbio.03653-25?af=R

____

My New Space

Most Popular Posts